-
Biogen Unusual Options Activity For April 18
18 Apr 2024 19:39 GMT
… 36 extraordinary options activities for Biogen. This level of activity … 0K
1.5K
522
About Biogen
Biogen and Idec merged in … a collaboration with Roche. Biogen also markets novel multiple sclerosis … market status and performance.
Biogen's Current Market …
-
Biogen CEO Viehbacher sees 2023 pay fall to $4M after massive welcome package
17 Apr 2024 00:25 GMT
… flagship spinal muscular atrophy franchise. Biogen made some progress last year … amyotrophic lateral sclerosis patients.
As Biogen reorganizes its internal pipeline, the … innovation for future growth points. Biogen last year acquired Reata Pharmaceuticals …
-
AAN 2024: Importance of early diagnosis and prompt treatment in SMA
19 Apr 2024 15:46 GMT
… availability of disease-modifying therapies, Biogen’s Spinraza, Roche’s Evrysdi …
-
Global Quantum Technology Market Research 2024-2029 with Assessment of Companies Focused on Quantum Technology, R&D Efforts and Potential Game-changing Quantum Tech-enabled Solutions - ResearchAndMarkets.com
19 Apr 2024 17:11 GMT
… Inc. (InVisage Technologies)
4.14 Biogen Inc.
4.15 Block Engineering …
-
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
19 Apr 2024 12:15 GMT
… , Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie …
-
Episode 113: Lessons Learned in Alzheimer Drug Development
19 Apr 2024 12:08 GMT
… recent discontinuation of aducanumab (Aduhelm; Biogen), and the potential and limitations …
-
Amgen CEO nabs pay raise thanks to Horizon deal. Does that incentivize aggressive M&A?
19 Apr 2024 03:01 GMT
… rules as Amgen. For example, Biogen excluded revenues from the newly … ’s 2023 pay. Amgen lists Biogen as a peer company in …
-
Eli Lilly’s double impact: Mounjaro and Donanemab to ‘outshine’ market rivals from BioPharma-Reporter.com
18 Apr 2024 22:15 GMT
… ’s answer to Eisai and Biogen’s Leqembi (lecanemab), has emerged …
-
Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win
18 Apr 2024 21:46 GMT
… to get into the space.
Biogen and Sage Therapeutics tried to …
-
AbbVie touts Rinvoq win in giant cell arteritis, potentially teeing up another label expansion
18 Apr 2024 18:47 GMT
… has approved Actemra biosimilars from Biogen and Fresenius Kabi in recent …